FYJ-195: Potency Data for a FLT3 Inhibitor Against Drug-Resistant AML Mutations

Experimental data describes the discovery and characterization of FYJ-195, a type II FLT3 inhibitor for acute myeloid leukemia. The dataset includes in vitro IC50 values against specific resistance mutations and in vivo tumor growth inhibition results from xenograft models. Jin Yang authored this dataset, which was last updated on 2026-05-23.

Use Cases

• Compare inhibitor potency based on IC50 values against FLT3-ITD-F691L and D835V/Y mutants mentioned in the description
• Analyze in vivo efficacy based on tumor growth inhibition percentages from MV4-11 and Ba/F3-FLT3-ITD-F691L models
• Benchmark new FLT3 inhibitors against the reported activity of FYJ-195 and quizartinib
• Study structure-activity relationships for type II FLT3 inhibitors based on the optimization from lead compound SILA-123

Strengths

• Includes specific, single-digit nanomolar and subnanomolar IC50 values (e.g., 9.09 nM, 0.76 nM) for key resistance mutations
• Reports quantitative in vivo efficacy metrics, including 125% tumor regression and 68.6% growth suppression
• Data is associated with a clear, peer-reviewed research narrative published on figshare

Limitations

• Dataset is very small at 5.6 KB, indicating limited scope and likely a focused summary of key results
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment for statistical analysis

Provenance

Source

figshare

Collection Method

Likely contains results from structure-guided optimization, biochemical assays, and in vivo xenograft studies as described.

Freshness

Last updated 2026-05-23 13:35:03; freshness should be verified